Lexeo Therapeutics (LXEO) Financials

Lexeo Therapeutics remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is characterized by recurring operating losses, significant research spending and reliance on equity financing, although the company has strengthened its liquidity position substantially since 2023.

• Liquidity improved in Q2 2026. Cash and equivalents increased to $92.8 million from $71.8 million in Q1, while short-term investments totaled $118.9 million. Including long-term investments, Lexeo held approximately $240 million in cash and investments at quarter-end.
• The balance sheet has limited leverage. Total liabilities were $19.8 million compared with $235.1 million of equity, and the company reported no current or long-term debt balances in the supplied Q2 2026 data. Total current assets of $217.9 million were approximately 13.9 times current liabilities of $15.7 million.
• Quarterly operating cash burn moderated. Net cash used in operating activities declined to $18.0 million in Q2 2026 from $21.1 million in Q1 2026 and $27.2 million in Q2 2025. This suggests some improvement in near-term cash management, although the company remains cash-flow negative.
• Investment income provides a modest offset to operating losses. Interest and investment income was $2.2 million in Q2 2026, helping reduce the pretax loss from the $28.0 million operating loss to $25.9 million.
• Research spending remains substantial. Research and development expense was $19.0 million in Q2 2026, up from $15.7 million in Q1 2026 and $14.7 million in Q2 2025. For a biotechnology company, continued investment may support clinical development and pipeline progress if programs advance successfully.
• Cash growth has been driven primarily by financing and investment activity rather than operations. Q2 2026 financing activities provided $24.3 million, including $24.9 million from common-stock issuance, while investing activities added $14.3 million largely because investment maturities exceeded purchases. These sources of cash may not be recurring.
• Total assets have fluctuated with financing and investment activity. Assets increased to $254.9 million in Q2 2026 from $143.8 million in Q3 2025, but the change largely reflects capital raises and shifts between cash and investments rather than operating growth.
• Lexeo has not generated revenue. Total revenue was reported at zero in every income statement period supplied, leaving the company dependent on its cash reserves, investment income, partnerships or future financing until products or programs generate commercial revenue.
• Losses remain persistent. Net losses were approximately $20.2 million to $32.7 million per quarter across the supplied 2025 and 2026 periods. The Q2 2026 net loss was $25.9 million, compared with $20.2 million in Q1 2026 and $26.1 million in Q2 2025.
• Shareholder dilution has been significant. Weighted-average basic shares outstanding increased from 33.1 million in Q1 2024 to 85.6 million in Q2 2026. Recent equity issuance, including $153.7 million in Q4 2025 and $24.9 million in Q2 2026, has helped fund operations but increases the share base and can reduce existing investors’ ownership percentage.

Overall, Lexeo’s strongest financial advantage is its sizable cash and investment portfolio relative to liabilities. However, the company continues to consume cash, report no revenue and accumulate losses, with retained earnings reaching a deficit of $426.2 million by Q2 2026. Investors should focus on clinical and regulatory progress, future financing needs and whether operating cash burn remains manageable.